Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be safe and have efficacy in patients with mCRPC. The dose-escalation phase (Part 1) will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and/or recommended dose and schedule for the subsequent expansion phase (Part 2).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku 18 lat lub starszy
- •Potwierdzona histologicznie lub cytologicznie gruczolakorak prostaty
- •Wcześniejsza kastracja chirurgiczna lub leczenie hormonalne obniżające testosteron poniżej 50 ng/dL
- •Wcześniejsze leczenie nowoczesną hormonoterapią (np. abiraterone, enzalutamide, apalutamide)
- •Kwalifikacja do terapii lutetem-177 PSMA-617 z co najmniej jednym zmienionym ogniskiem
- •Postępujący zaawansowany rak prostaty oporny na kastrację
- •Dobra kondycja ogólna (skala ECOG 0-1)
- •Prawidłowe wartości laboratoryjne (liczba białych krwinek, płytki, wątroba, nerki)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Huntsman Cancer Institute at University of Utah
Salt Lake City, United States
Trial contact
Susan Sharry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.